Zobrazeno 1 - 10
of 26
pro vyhledávání: '"James M. Pauff"'
Autor:
Michal Kwiatek, Guru Subramanian Guru Murthy, Marc Hoffmann, Lindsey Roeker, Benoit Tessoulin, Alexey Danilov, Alvaro J. Alencar, Nirav N. Shah, Herve Ghesquieres, Steven Le Gouill, Wojciech Jurczak, Anthony R. Mato, Vishalkumar Patel, Yingying Guo-Avrutin, James M. Pauff, Maciej Kazmierczak
Publikováno v:
HemaSphere, Vol 7, p e216785f (2023)
Externí odkaz:
https://doaj.org/article/88e61ece0ef54dbf9c6551b4c45ba994
Autor:
Jonathan L. Kaufman, Ahmed Salem, Xiaoqing Yang, James M. Pauff, Paulo Maciag, Cyrille Touzeau, Fredrik Schjesvold, Thierry Facon, Lawrence H. Boise, Shaji Kumar, Yanwen Jiang, Stefanie Unger, Wan-Jen Hong, Deeksha Vishwamitra, John Pesko, Fengjiao Dunbar, Yao Yu, Jeremy A. Ross, Cristina Gasparetto, Philippe Moreau, R. N. Tammy Macartney
Publikováno v:
American Journal of Hematology
American Journal of Hematology, Wiley, 2021, 96 (4), pp.418-427. ⟨10.1002/ajh.26083⟩
American Journal of Hematology, 2021, 96 (4), pp.418-427. ⟨10.1002/ajh.26083⟩
American Journal of Hematology, Wiley, 2021, 96 (4), pp.418-427. ⟨10.1002/ajh.26083⟩
American Journal of Hematology, 2021, 96 (4), pp.418-427. ⟨10.1002/ajh.26083⟩
International audience; Venetoclax (Ven) is a selective small-molecule inhibitor of BCL-2 that exhibits antitumoral activity against MM cells with t(11;14) translocation. We evaluated the safety and efficacy of Ven and dexamethasone (VenDex) combinat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17b21832e5c2e9835fad67a7c18bcf1a
https://www.hal.inserm.fr/inserm-03349233/file/Moreau2020Eq11.pdf
https://www.hal.inserm.fr/inserm-03349233/file/Moreau2020Eq11.pdf
Autor:
Vishalkumar Patel, Lindsey E. Roeker, Wojciech Jurczak, Alvaro J. Alencar, Nora Ku, Marc Hoffmann, James M. Pauff, Steven Le Gouill, Guru Subramanian Guru Murthy, Toby A. Eyre
Publikováno v:
Blood. 138:2424-2424
Background: B-cell lymphoma 2 (BCL2) is a key regulator of apoptosis and provides protection from cell death in many hematological malignancies. The BCL2 inhibitor venetoclax is approved for the treatment of CLL/SLL and acute myeloid leukemia and has
Autor:
Jabeen Ahmad, Hans Peter Bacher, Mondira Bhattacharya, Deepa H. Chand, Monali Desai, Thao Doan, James Duhig, Vicki Edwards, Jawed Fareed, Carl Fischer, Cheryl Foit, Suzanne Pauline Green, Barbara A. Hendrickson, Robert Hogan, Syed S. Islam, Calvin Johnson, Jeremy D. Jokinen, Ryan Kilpatrick, Karolyn Kracht, Gweneth Levy, Fabio Lievano, Murray Malin, Anthony G. Oladipo, Denise M. Oleske, Meenal Patwardhan, James M. Pauff, Ariel Ramirez Porcalla, Radhika M. Rao, Nicholas Rees, Cheryl Renz, Adrienne M. Rothstein, Linda Scarazzini, Charles Schubert, Sundeep Sethi, Arsalan Shabbir, Melissa M. Truffa, Jerzy Edward Tyczynski, Marietta Vazquez, Verghese Mathew
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9cd33e07d5ff1b05dd4700bc7c7c2a6d
https://doi.org/10.1016/b978-0-323-58116-5.01002-6
https://doi.org/10.1016/b978-0-323-58116-5.01002-6
The objective of this chapter is to provide an overview of safety planning and monitoring along with the analysis and communication of clinical trial safety data. Safety planning requires an assessment of the available information relevant to the saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92d5f53583f21cc6b111b9150a482c74
https://doi.org/10.1016/b978-0-323-58116-5.00003-1
https://doi.org/10.1016/b978-0-323-58116-5.00003-1
Autor:
Shaji Kumar, Jeremy A. Ross, Wan-Jen Hong, Hans Salwender, Simon J. Harrison, Michele Cavo, Paulo Maciag, Michael O'Dwyer, Xiaoqing Yang, Javier de la Rubia, Philippe Moreau, Kenshi Suzuki, Rakesh Popat, Inho Kim, Vania Hungria, Andrew Spencer, James M. Pauff, Muhammad Jalaluddin
Publikováno v:
Journal of Clinical Oncology. 38:8547-8547
8547 Background: Venetoclax (Ven) is a selective, potent BCL-2 inhibitor that has synergistic activity with bortezomib (B) and dexamethasone (d). In the Phase 3 BELLINI trial, addition of Ven to Bd significantly improved median progression-free survi
Autor:
Beenish S Manzoor, George A. Follows, Paul M. Barr, Maryam Sarraf Yazdy, Irina Pivneva, Daniel Dingfeng Jiang, Chaitra S. Ujjani, Bruce D. Cheson, Anthony R. Mato, Toby A. Eyre, Mazyar Shadman, Jennifer R. Brown, German Pena, Danielle M. Brander, Jacqueline Nielsen, John N. Allan, Simon Sharmokh, James M. Pauff, Nicole Lamanna, Rajat Bannerji, Lindsey E. Roeker, Thomas S. Marshall, William G. Wierda, Hande H. Tuncer, Barbara Eichhorst, Kavita Sail, Anna Schuh, Brian T. Hill, Alan P Skarbnik, Stephen J. Schuster
Publikováno v:
Blood. 134:1756-1756
BACKGROUND Novel agents have changed the treatment landscape in chronic lymphocytic leukemia (CLL), however little has been reported about real-world treatment sequence patterns and associated outcomes post-introduction of novel agents. Studies have
Autor:
Lawrence H. Boise, Cyrille Touzeau, Thierry Facon, James M. Pauff, Wan-Jen Hong, John Pesko, Cristina Gasparetto, Philippe Moreau, Tammy Macartney, Ahmed Salem, Paulo Maciag, Jeremy A. Ross, Shaji Kumar, Fredrik Schjesvold, Jonathan L. Kaufman, Stefanie Alzate
Publikováno v:
Blood. 134:926-926
Background Venetoclax (Ven) is a selective, small molecule inhibitor of anti-apoptosis protein Bcl-2 that has antitumoral activity against multiple myeloma (MM), notably those with translocation t(11;14). Dexamethasone (d) has shown to enhance the ex
Autor:
Nicole Lamanna, Anna Schuh, Bruce D. Cheson, Chaitra S. Ujjani, George A. Follows, James M. Pauff, Paul M. Barr, Annie Guerin, Nnadozie Emechebe, Jennifer R. Brown, Toby A. Eyre, Rajat Bannerji, Rajesh Kamalakar, Daniel Dingfeng Jiang, John N. Allan, Simon Sharmokh, Jacqueline Nielsen, Anthony R. Mato, Thomas S. Marshall, Hande H. Tuncer, Mazyar Shadman, German Pena, Maryam Sarraf Yazdy, Barbara Eichhorst, William G. Wierda, Kavita Sail, Lindsey E. Roeker, Irina Pivneva, Beenish S Manzoor, Brian T. Hill, Alan P Skarbnik, Stephen J. Schuster, Danielle M. Brander
Publikováno v:
Blood. 134:3048-3048
BACKGROUND The recent approval of novel agents (NAs) has changed the treatment landscape in chronic lymphocytic leukemia (CLL), however, there remains uncertainty regarding treatment discontinuation patterns in real-world (RW) settings. This study as
Autor:
Jeremy A. Ross, Joel D. Leverson, Tamar Uziel, James M. Pauff, Dipica Haribhai, Paulo Maciag, Orlando F. Bueno, Deeksha Vishwamitra, Christine Mantis
Publikováno v:
Blood. 134:1896-1896
Background: The BCL-2 family of anti-apoptotic proteins (e.g., BCL-2, BCL-XL, MCL-1) are important regulators of lymphocyte development and are therapeutic targets for hematologic malignancies, including multiple myeloma (MM). Venetoclax (Ven) is a h